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Abstract: Protein toxins produced by bacteria are the cause of
many life-threatening diarrheal diseases. Many of these toxins,
including cholera toxin (CT), enter the cell by first binding to
glycolipids in the cell membrane. Inhibiting these multivalent
protein/carbohydrate interactions would prevent the toxin
from entering cells and causing diarrhea. Here we demonstrate
that the site-specific modification of a protein scaffold, which is
perfectly matched in both size and valency to the target toxin,
provides a convenient route to an effective multivalent
inhibitor. The resulting pentavalent neoglycoprotein displays
an inhibition potency (IC50) of 104 pm for the CT B-subunit
(CTB), which is the most potent pentavalent inhibitor for this
target reported thus far. Complexation of the inhibitor and
CTB resulted in a protein heterodimer. This inhibition strategy
can potentially be applied to many multivalent receptors and
also opens up new possibilities for protein assembly strategies.
Many viruses, bacteria, and protein toxins adhere to their
target cells by binding to specific cell-surface carbohydrates.
Diarrheal diseases that are initiated in this way account for
around two million deaths annually.[1] For example, cholera is
caused by an AB5 protein toxin that has a single toxic A-
subunit associated with five nontoxic B-subunits (CTB),
which constitute a pentameric receptor for the GM1 glyco-
lipid found on the surface of intestinal epithelial cells.[2]
Multivalent binding between CTB and up to five copies of
its GM1 ligand facilitates the entry of the toxin into the cell by
endocytosis.
Multivalency is a common feature of cell-surface adhesion
and has thus provided the primary focus for creating
inhibitors of carbohydrate-binding proteins, including
CTB.[3] Polymeric structures and dendrimers with either
galactosyl residues or the more strongly binding GM1
oligosaccharide (GM1os) ligands have demonstrated the
potential improvements in activity that multivalency can
provide.[4] Pentavalent star-shaped structures that match the
valency and positioning of the ligand groups to CTB have
been shown to be some of the most successful inhibitors. A
pentacyclen core with galactose ligands was used by Fan and
co-workers to produce an inhibitor with a reported IC50 value
of 1.4 mm.[5] Their modular approach showed that matching
precisely the size and spacing of the ligands to the binding
sites of CTB could optimize the inhibitory potential.[5b,6]
Other recent studies have used GM1os ligands on both
corannulene[7] and calixarene cores.[8] These pentavalent
structures gave IC50 values down to 5 nm and 450 pm,
respectively. A pentameric carbohydrate core has also been
used in the highly effective Starfish ligands for shiga-like
toxin.[9] While synthetic pentavalent ligands have proven to be
effective inhibitors, the synthesis of large (> 5 nm diameter),
precisely defined multivalent scaffolds is very challenging and
hampers larger-scale applications.
Here we report a multivalent inhibitor for cholera toxin,
based on an inactive mutant CTB protein that is modified
with GM1os ligands (Figure 1). As the majority of the
structure comes as a ready-made building block, the synthetic
route to the inhibitor is relatively short. Previous attempts to
introduce sugars at defined sites on an ankyrin repeat
protein[10] and the barstar protein[11] led to ligands and
inhibitors of plant lectins. However, as no attempts were
made to match the size and spacing of the ligands to the
binding sites, these multivalent compounds led to only modest
enhancements in activity and/or lectin aggregation, which
may be undesirable. In the example reported here, the
pentavalent inhibitor is matched to the size and valency of the
target CTB protein, which leads to defined complexes and
potent inhibition.
We postulated that by using an inactive mutant CTB
protein as the scaffold, once modified with carbohydrates, the
resulting pentavalent ligand should provide a precise fit of the
ligand groups with the spacing and configuration of binding
sites on wild-type CTB (Figure 1). The CTB homopentamer
has five N-terminal threonine residues situated on the protein
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surface toward the ligand-binding face and equally spaced
around the protein between the GM1 binding sites. These
residues bear unique vicinal amino alcohol groups, which can
be selectively converted by oxidation to an aldehyde before
reaction with an oxyamine.[12] Modification of the protein
scaffold at these sites with five GM1os ligands would result in
a pentavalent ligand. As proteins of this class can be prepared
in large quantities, the synthesis is potentially scalable.[13]
The GM1os ligand was prepared by first synthesizing Boc-
protected aminooxy alkyne 3 (Scheme 1) according to
a reported procedure.[14] GM1 azide 2 was prepared using
a chemo-enzymatic approach[15] before ligation to aminooxy
alkyne 3 employing a copper-catalyzed alkyne azide cyclo-
addition (CuAAC) at room temperature with stirring for
48 hours. Attempts were made to use microwave-assisted
CuAAC for the synthesis,[16] but proved unsuccessful in this
case. After purification by reverse-phase column chromatog-
raphy, the GM1os ligand 4 was isolated. The Boc group was
removed with TFA to form oxyamine 5, directly prior to the
attachment to the protein without further purification (to
preserve the highly reactive aminooxy group).
To create the protein scaffold, a nonbinding mutant of
CTB was required. Based on the work of Jobling and
Holmes,[17] a tryptophan residue (W88) in the GM1 binding
pocket was changed to a glutamic acid residue by site-directed
mutagenesis. The resulting CTB mutant protein (W88E) was
no longer capable of binding to GM1os (Figure S3 in
Supporting Information). The five N-terminal vicinal amino
alcohol groups in W88E were then oxidized with NaIO4
(Scheme 1) to give aldehydes, which were observed in their
hydrated form W88E(ox) by ESI–MS (found: 11557.8 Da;
calcd: 11 557.9 Da). The oxidized protein was then allowed to
react with deprotected oxyamine 5 in the presence of aniline
at pH 7. Aniline is known to be an effective catalyst of oxime
formation at pH 4.5,[18] however, as the CTB protein dena-
tures under acidic conditions, a neutral pH value was used and
the reaction still proceeded to completion within 24 hours.
Pentavalent ligand W88E(GM1) was purified by size-exclu-
sion chromatography (SEC) and ESI–MS confirmed that the
modified protein had a mass of 12844.5 Da (calcd:
12844.4 Da; Figure S1). SDS-PAGE confirmed that the
modification did not disrupt the pentameric form of the
protein and no protein aggregation was observed (Figure S1).
An enzyme-linked lectin assay (ELLA) was performed to
determine the inhibitory potential of the neoglycoprotein.[7,8]
The ability of CTB to bind to a GM1-coated microtiter plate
was assessed across a wide range of inhibitor concentrations.
Pentavalent ligand W88E(GM1) exhibited an exceptionally
low IC50 value of 104 pm (Figure 2 and Table 1), making it the
most potent pentavalent ligand reported thus far. This IC50
value corresponds to a 5100-fold enhancement compared to
monovalent GM1os 1, or 14300-fold enhancement compared
to monovalent GM1 azide 2. The unmodified W88E protein
as a control showed no inhibition of CTB binding to a GM1-
coated microtiter plate.
Isothermal titration calorimetry (ITC) was used to
analyze the interaction between pentavalent protein-based
inhibitor W88E(GM1) and wild-type CTB. W88E(GM1) was
titrated into a solution of CTB and the expected binding
stoichiometry of one GM1os ligand per binding site was
Figure 1. Strategy for re-engineering the CTB protein to prepare
a pentavalent neoglycoprotein inhibitor for cholera toxin. The N termini
of a nonbinding CTB mutant W88E are oxidized to give aldehydes that
undergo oxime ligation with a carbohydrate ligand that bears an
aminooxy function. The resulting neoglycoprotein has ligand groups
arranged with optimal spacing to bind to the cholera toxin protein. In
the 3D structure of CTB (PDB code: 3CHB),[24] the binding sites are
marked in white, and N-terminal threonine residues are marked with
black arrows.
Scheme 1. a) Synthesis of an oxime-modified GM1 oligosaccharide
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observed, which is consistent with a binding model in which
W88E(GM1) forms a protein heterodimer complex with
CTB. However, an apparent Kd of 30 nm was detected, similar
to that of the monovalent GM1 azide 2, which had a Kd of
56 nm (Figure S3 and Table S1), and that of GM1os 1 (43 nm),
which was used in previous studies.[20] The similarity between
the affinities of mono- and pentavalent ligands contrasts with
affinity enhancements reported for other multivalent sys-
tems.[21] However, the result is in line with our previous
studies of GM1-based dendrimers,[22] in which it was con-
cluded that a mismatch in valency between dimeric or
tetrameric inhibitors and a pentavalent protein resulted in
an aggregative mechanism of inhibition. In contrast, Fan and
co-workers reported that their pentavalent ligands gave only
1:1 complexes in dynamic light scattering (DLS) and crystal-
lization studies, and no larger aggregates were observed.[23]
Therefore, DLS and analytical ultracentrifugation (AUC)
experiments were used to determine if 1:1 complexes or larger
aggregates had formed between CTB and W88E(GM1).
DLS was first used to determine the size of the assemblies
(Figure 3a). The crystal structure of CTB shows the pentamer
to have a diameter of 6.5 nm and a depth of 3.5 nm.[24] These
measurements are consistent with the experimental hydro-
dynamic diameter of 5.6 nm. At a 1:1 ratio of CTB and
W88E(GM1), DLS showed a single peak at 8.4 nm. A face-to-
face dimer would have dimensions of 6.5 nm by at least 7 nm,
which was in agreement with the result from DLS. Increasing
the ratio of CTB to W88E(GM1) to 5:1 gave a similar result
with no larger aggregates. The observations from the DLS
experiment indicated that only a protein heterodimer of
pentamers is formed.
Sedimentation velocity AUC was used to further study the
oligomerization state of the protein complexes being formed
by ligand binding. At a ratio of 1:1 CTB and W88E(GM1),
AUC showed two peaks with sedimentation coefficients of
6.3 S and 3.6 S, corresponding to masses of approximately
110 kDa and 50 kDa, respectively (Figure 3b), which are
consistent with the predicted masses of a dimer of protein
pentamers and the single pentamer. The smaller peak at 3.6 S
was likely due to the concentrations of the two components
not being exactly equal. When the concentration of ligand
W88E(GM1) was decreased, so that CTB was now in excess
at a ratio of 5:1, the peak for the protein pentamer dominated,
but the peak for a dimer of pentamers was still seen. This
result showed that even with an excess of CTB, the only
protein complex observed was a heterodimer of protein
pentamers. No larger peaks were observed in the AUC
experiment and there was negligible change in the protein
absorbance after the AUC experiments, indicating that no
protein was lost through the formation and pelleting of large
Figure 2. Enzyme-linked lectin assay (ELLA) indicates the inhibitory
potential of W88E(GM1) and analogous monovalent ligands 1 and 2.
Error bars indicate the standard error of three measurements.
Table 1: Inhibitory potential results from the enzyme-linked lectin assay (ELLA).
Inhibitor Valency log(IC50) IC50 [nm]
[a] Relative potency (per GM1 group)[b] Hill coefficient
2 (GM1 azide) 1 5.830.16 1460 1 (1) 1.00.2
1 (GM1os) 1 6.270.04 530 2.75 (2.75) 0.90.1
W88E(GM1) 5 9.980.08 0.104 14300 (2860) 2.10.5
W88E 0 –[c] –[c] –[c] –[c]
[a] As curve fitting was performed with log[inhibitor] as x values, the fitting errors for IC50 values became asymmetric about the mean and were omitted
for simplicity. [b] Potency was measured relative to monovalent GM1 azide 2. [c] No inhibition detected.
Figure 3. a) Dynamic light scattering (DLS) results showing the
increase in the size of the particles when CTB is mixed at a ratio of 1:1
with W88E(4). b) Sedimentation coefficient distributions [c(s)] of CTB
mixed with W88E(4) at different ratios and the appearance of a single
species corresponding to a protein heterodimer.
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aggregates.[22] Nevertheless, it is still possible that at the
inhibitor concentration used in these biophysical experiments
(ca. 50000 times higher than the IC50 concentration for
W88E(GM1) in the ELLA), random aggregates could
initially form with modest binding affinities, as observed in
our ITC experiments.[25] If those aggregates were to rearrange
more slowly to form the thermodynamically preferred 1:1
complexes observed by DLS and AUC,[26] then this latter
process would probably be undetectable during the ITC
experiment, as the net enthalpy change for reorganization of
the aggregates would probably be very small. It would be
expected that 1:1 complexes should form directly at the much
lower concentrations of W88E(GM1) inhibitor used in the
ELLA.
SDS-PAGE performed on the AUC samples showed
bands for the pentameric protein and a dimer of pentamers in
the same ratios observed in the AUC experiments for the 1:1
and 5:1 mixtures of CTB and W88E(GM1) (Figure S1).
Therefore, the interactions forming the protein heterodimers
were sufficiently strong to survive the denaturing conditions
of SDS-PAGE.
In conclusion, the combination of DLS, AUC, and SDS-
PAGE confirmed that protein-based pentavalent ligand
W88E(GM1) bound to CTB in a 1:1 ratio, forming protein
heterodimers. With an IC50 value of 104 pm, this inhibitor is
the most potent pentavalent structure described thus far. By
using a protein scaffold that matches the size and the spacing
between binding sites and ligands, it is possible to control the
structure of the complexes that are formed.[3c] With the
growing interest in ligand-mediated protein assembly, it is
possible that tailored glycoproteins of this type could also be
used for the preparation of nanostructured protein materi-
als.[27] Furthermore, the protein-based inhibitor reported here
also has the advantage that it is relatively easy to synthesize.
Proteins of this type can be produced on an industrial scale[13]
and the reaction to modify the protein is simple. While the
synthesis of the carbohydrate moiety itself is not trivial,[15] the
combined use of protein modification and enzymatic oligo-
saccharide synthesis provides an attractive strategy for
biopharmaceutical synthesis. This work demonstrates a gen-
eral strategy for the creation of multivalent inhibitors of
protein/carbohydrate interactions.
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